Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms

TORONTO–(BUSINESS WIRE)–Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus: Nutraceuticals – Innovations through the Company’s Quicksome™ technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture – … [Read more…]

X-Ray Inspection Systems Market Report: Global Forecasts (2025-2032) by Component, System Type, Technology Type, Mode of Operation, Application, End-Use Industry, Distribution Channel and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “X-Ray Inspection System Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering. Market research reveals the X-Ray Inspection System Market is poised for significant growth, projected to increase from USD 1.63 billion in 2024 to USD 2.59 billion by 2032 at a CAGR of 5.96%. As quality control and safety standards … [Read more…]

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR … [Read more…]

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology … [Read more…]

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted … [Read more…]

Akumin Announces Agreement that will Solidify Long-Term Financial Foundation to Support Continued Growth and Patient Care

PLANTATION, Fla.–(BUSINESS WIRE)–Akumin Inc. (together with its subsidiaries “Akumin” or the “Company”) announced today that it entered into an agreement (the “Support Agreement”) with certain noteholders representing over 95% of outstanding senior secured notes due in 2027 and 2028 (together, the “Senior Secured Notes”), and Stonepeak, a leading alternative investment firm, that will reduce debt, … [Read more…]

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) … [Read more…]

OTC Drugs Market Intelligence Report 2025-2032: Revenues to Grow by $47 Billion with Accelerated Growth in Plant-based and Organic OTC Supplements Driven by Wellness-Focused Millennial Demographics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Over The Counter Drugs Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The Over The Counter Drugs Market is experiencing fundamental shifts as self-care gains traction across healthcare models. Senior leaders face complex choices as digitalization, regulatory adjustments, and evolving consumer behaviors redefine sector dynamics and competitive priorities. Market … [Read more…]

Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujarat, India

The INR 648 crore facility will drive investment in state-of-the-art biologics manufacturing facility in Pipan, Gujarat The facility will enhance technical capabilities, improve global competitiveness, and create long-term, high-value employment across scientific, technical, and operational disciplines AHMEDABAD, India–(BUSINESS WIRE)–Kashiv BioSciences Private Limited (“Kashiv”), a biopharmaceutical company, today announced that it has secured financing of INR … [Read more…]

Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in Parkinson’s Disease

SUGAR LAND, Texas–(BUSINESS WIRE)–#biopharma–Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ allogeneic adipose‑derived mesenchymal stem cell therapy (HB-adMSCs) for patients with early to moderate Parkinson’s Disease (PD), a condition currently considered incurable that affects approximately one million in the … [Read more…]